In this study, we identified a novel strategy that inhibits TCR activation, in which transferrin directly binds to TRAC to inhibit the formation of the TCR–CD3 signaling complex, block TCR signaling, and consequently suppress anti-metastatic and anti-tumor immunity. This evidence concerns the gene TRAC and neoplasm.